Skip to contentSkip to filters

We use cookies for analytics.

Medicinal Evolution of Natural Hormones to Transform Drug Treatment of Obesity

Richard DiMarchi

Indiana University

Abstract

The epidemic of obesity and its associated comorbidities is a medicinal challenge that warrants broad molecular diversity. This lecture describes work, with many collaborators, recruiting endogenous hormones and physiological mechanisms optimized for pharmacological purposes to address the heterogeneity of the multiple diseases associated with the metabolic syndrome. From the earliest demonstration with lispro-insulin to the recent discovery of single-molecule, mixed incretin agonists, the work has pursued chemically optimized macromolecules for the management of endocrine and related diseases, integrating classical small- and large-molecule pharmacology while advancing chemical methods for synthesizing complex macromolecules. The integrated pharmacology of these peptides, proteins and nuclear hormones has produced a library of drug candidates replicated across academic and commercial laboratories and clinical studies and has inspired registered drugs with transformative therapeutic outcomes. The methodological approach may also have merit in the search for medicines for other complex diseases associated with advanced age.

Topics